Edgar Filing: ALEXION PHARMACEUTICALS INC - Form 4

ALEXION PHARMACEUTICALS INC

Form 4

August 24, 2016

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB 3235-0287 Number:

January 31, Expires: 2005

burden hours per response... 0.5

Estimated average

if no longer subject to Section 16. Form 4 or Form 5

obligations

may continue.

See Instruction

Check this box

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

SECURITIES

30(h) of the Investment Company Act of 1940

1(b).

(Last)

(City)

share

C/O ALEXION

(Print or Type Responses)

1. Name and Address of Reporting Person * 5. Relationship of Reporting Person(s) to 2. Issuer Name and Ticker or Trading PARVEN ALVIN S Issuer Symbol ALEXION PHARMACEUTICALS (Check all applicable)

3. Date of Earliest Transaction

INC [ALXN]

(Middle)

(Zip)

_X__ Director 10% Owner

(Month/Day/Year)

08/15/2016

Other (specify Officer (give title

PHARMACEUTICALS, INC, 100

(State)

(First)

COLLEGE STREET

(Street) 4. If Amendment, Date Original 6. Individual or Joint/Group Filing(Check

Filed(Month/Day/Year)

Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting

NEW HAVEN, CT 06510

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

` *	· · · · ·	Tab	ie 1 - Noii-i	Derivative	Secur	iues Acqui	rea, Disposea oi,	or benefician	y Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securit or Dispos (Instr. 3, 4	ed of (5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock, par value \$.0001 per share	08/15/2016		S	700	D D	\$	6,373	D	
Common Stock, par value \$.0001 per	08/22/2016		M	15,000	A	\$ 18.01	21,373	D	

Edgar Filing: ALEXION PHARMACEUTICALS INC - Form 4

Common

Stock, par

S 136.53 6,373 value 08/22/2016 15,000 D D

(2) \$.0001 per

share

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control number.

15,000

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4. 5. Number of		6. Date Exercisable and		7. Title and Amount of	
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	TransactionDerivative		Expiration Date		Underlying Securities	
Security	or Exercise		any	Code Securities		(Month/Day/Year)		(Instr. 3 and 4)	
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)	Acquired (A)				
	Derivative				or Disposed of				
	Security				(D)				
	•				(Instr. 3, 4,				
					and 5)				
									Amount
						Date	Expiration	m: a	or
						Exercisable	Date	Title	Number
				Code V	(A) (D)				of Shares
								C	
Ontion to								Common	

Option to Stock, par Purchase \$ 18.01 08/22/2016 M 15,000 08/09/2008 05/09/2018 value Common

\$.0001 Stock per share

Reporting Owners

Relationships Reporting Owner Name / Address

> 10% Owner Officer Other Director

PARVEN ALVIN S C/O ALEXION PHARMACEUTICALS, INC 100 COLLEGE STREET NEW HAVEN, CT 06510

X

Signatures

/s/ Alvin Parven 08/24/2016

**Signature of Date

Reporting Person

Reporting Owners 2

Edgar Filing: ALEXION PHARMACEUTICALS INC - Form 4

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- This transaction was executed in multiple trades through a broker-dealer at prices ranging from \$135.00 \$135.99. The price reported in
- (1) this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.
- This transaction was executed in multiple trades through a broker-dealer at prices ranging from \$136.00 \$136.99. The price reported in
- (2) this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.